Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Receivables - Other (2016 - 2024)

Historic Receivables - Other for Sangamo Therapeutics (SGMO) over the last 16 years, with Q4 2024 value amounting to $4.1 million.

  • Sangamo Therapeutics' Receivables - Other rose 91736.97% to $4.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $4.1 million, marking a year-over-year increase of 91736.97%. This contributed to the annual value of $4.1 million for FY2024, which is 91736.97% up from last year.
  • Sangamo Therapeutics' Receivables - Other amounted to $4.1 million in Q4 2024, which was up 91736.97% from $10.0 million recorded in Q3 2024.
  • Sangamo Therapeutics' Receivables - Other's 5-year high stood at $10.0 million during Q3 2024, with a 5-year trough of $289000.0 in Q2 2022.
  • Over the past 5 years, Sangamo Therapeutics' median Receivables - Other value was $800500.0 (recorded in 2021), while the average stood at $1.4 million.
  • As far as peak fluctuations go, Sangamo Therapeutics' Receivables - Other crashed by 6628.02% in 2021, and later soared by 156112.96% in 2024.
  • Sangamo Therapeutics' Receivables - Other (Quarter) stood at $1.0 million in 2020, then plummeted by 66.28% to $349000.0 in 2021, then surged by 127.51% to $794000.0 in 2022, then plummeted by 49.24% to $403000.0 in 2023, then soared by 917.37% to $4.1 million in 2024.
  • Its Receivables - Other stands at $4.1 million for Q4 2024, versus $10.0 million for Q3 2024 and $403000.0 for Q4 2023.